Payment overview · 2025
General Payments
$1,186.76
43 reported records · 23 companies
Healthcare provider profile · identity verified
Danielle M Mrozienski, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CASSELBERRY, FL · NPI 1164829545
Verified facts
What the public records show
CMS Open Payments records show Danielle M Mrozienski, APRN received $1,186.76 in general payments during 2025 across 43 reported records.
Eisai Inc. accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $159.64 | 13.4% | 4 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $151.13 | 12.7% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $120.11 | 10.1% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $103.98 | 8.8% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $78.99 | 6.7% | 3 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $77.17 | 6.5% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$65.68 | 5.5% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $44.61 | 3.8% | 2 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $40.34 | 3.4% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $40.08 | 3.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.70 | 3.4% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.25 | 3.0% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $30.76 | 2.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.75 | 2.2% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $24.15 | 2.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.84 | 2.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $21.03 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.72 | 1.7% | 1 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$19.71 | 1.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.11 | 1.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.36 | 1.4% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.04 | 1.4% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.61 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,186.76 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $238.63 | 7 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $120.11 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $82.88 | 3 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $77.17 | 3 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $68.25 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $65.68 | 3 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $44.61 | 2 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $40.34 | 2 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $40.08 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.70 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.70 | 2 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $35.25 | 3 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $30.76 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.36 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 51 |
| Famotidine | Famotidine | 94 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 87 | 48 |
| Losartan Potassium | Losartan Potassium | 85 | 48 |
| Atorvastatin Calcium | Atorvastatin Calcium | 79 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 62 | 37 |
| Omeprazole | Omeprazole | 61 | 35 |
| Levothyroxine Sodium | Levothyroxine Sodium | 60 | 35 |
| Azithromycin | Azithromycin | 57 | 49 |
| Baclofen | Baclofen | 54 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 26 |
| Lisinopril | Lisinopril | 51 | 30 |
| Metformin Hcl | Metformin Hcl | 49 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 27 |
| Gabapentin | Gabapentin | 43 | 24 |
| Fluconazole | Fluconazole | 37 | 26 |
| Trazodone Hcl | Trazodone Hcl | 37 | 22 |
| Meloxicam | Meloxicam | 36 | 16 |
| Sertraline Hcl | Sertraline Hcl | 34 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 29 | 18 |
| Methylprednisolone | Methylprednisolone | 28 | 25 |
| Montelukast Sodium | Montelukast Sodium | 28 | 13 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | 13 |
| Carvedilol | Carvedilol | 26 | 18 |
| Nystatin | Nystatin | 25 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 18 |
| Furosemide | Furosemide | 23 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | 17 |
| Ibuprofen | Ibuprofen | 22 | 14 |
| Alprazolam | Alprazolam | 21 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | 11 |
| Ozempic | Semaglutide | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | 11 |
| Naproxen | Naproxen | 17 | 13 |
| Ofloxacin | Ofloxacin | 17 | 14 |
| Eliquis | Apixaban | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 15 |
| Prednisone | Prednisone | 16 | 14 |
| Azelastine Hcl | Azelastine Hcl | 15 | 12 |
| Glimepiride | Glimepiride | 15 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 15 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | 11 |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Simvastatin | Simvastatin | 13 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,186.76 · 43 records | Eisai Inc. | AUSTEDO XR, BREZTRI, CAPVAXIVE, CREXONT, DAYBUE, EPIDIOLEX, FYCOMPA, Fintepla, INBRIJA, INGREZZA, LEQEMBI, Motpoly XR, NURTEC ODT, Nayzilam, PRECIVITYAD2, QULIPTA, Qelbree, TRUDHESA, UBRELVY, UPLIZNA, VALTOCO, VYEPTI, ZAVZPRET | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error